{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T19:57:44Z","timestamp":1790452664029,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Comprehensive Psychiatry"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1016\/j.comppsych.2010.12.003","type":"journal-article","created":{"date-parts":[[2011,2,10]],"date-time":"2011-02-10T05:58:12Z","timestamp":1297317492000},"page":"107-115","source":"Crossref","is-referenced-by-count":35,"title":["Factors associated with adherence to treatment with olanzapine and other atypical antipsychotic medications in patients with schizophrenia"],"prefix":"10.1016","volume":"53","author":[{"given":"Hong","family":"Liu-Seifert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olawale O.","family":"Osuntokun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter D.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.comppsych.2010.12.003_bb0005","doi-asserted-by":"crossref","first-page":"453","DOI":"10.4088\/JCP.v67n0317","article-title":"Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care","volume":"67","author":"Ascher-Svanum","year":"2006","journal-title":"J Clin Psychiatry"},{"issue":"2\u20133","key":"10.1016\/j.comppsych.2010.12.003_bb0010","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0920-9964(97)00131-X","article-title":"Factors influencing relapse in the long-term course of schizophrenia","volume":"28","author":"Ayuso-Guti\u00e9rrez","year":"1997","journal-title":"Schizophr Res"},{"key":"10.1016\/j.comppsych.2010.12.003_bb0015","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1471-244X-8-32","article-title":"Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia","volume":"8","author":"Morken","year":"2008","journal-title":"BMC Psychiatry"},{"issue":"7","key":"10.1016\/j.comppsych.2010.12.003_bb0020","doi-asserted-by":"crossref","first-page":"990","DOI":"10.4088\/JCP.08m04221","article-title":"Medication non-adherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response","volume":"70","author":"Lindenmayer","year":"2009","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"10.1016\/j.comppsych.2010.12.003_bb0025","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1176\/ps.49.2.196","article-title":"Compliance with medication regimens for mental and physical disorders","volume":"49","author":"Cramer","year":"1998","journal-title":"Psychiatr Serv"},{"issue":"3","key":"10.1016\/j.comppsych.2010.12.003_bb0030","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0924-9338(02)00645-4","article-title":"Predictors of noncompliance in males with first-episode schizophrenia, schizophreniform and schizoaffective disorder","volume":"17","author":"Novak-Grubic","year":"2002","journal-title":"Eur Psychiatry"},{"issue":"9618","key":"10.1016\/j.comppsych.2010.12.003_bb0035","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","article-title":"Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial","volume":"371","author":"Kahn","year":"2008","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.comppsych.2010.12.003_bb0040","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1097\/JCP.0b013e318185e74a","article-title":"The temporal relationship between symptom change and treatment discontinuation in a pooled analysis of 4 schizophrenia trials","volume":"28","author":"Kinon","year":"2008","journal-title":"J Clin Psychopharmacol"},{"issue":"12","key":"10.1016\/j.comppsych.2010.12.003_bb0045","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.comppsych.2010.12.003_bb0050","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/01.jcp.0000245563.06660.0f","article-title":"Differential rates of treatment discontinuation in clinical trials as a measure of treatment effectiveness for olanzapine and comparator atypical antipsychotics for schizophrenia","volume":"26","author":"Kinon","year":"2006","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"10.1016\/j.comppsych.2010.12.003_bb0055","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/schbul\/sbm134","article-title":"Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia","volume":"34","author":"Ascher-Svanum","year":"2008","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.comppsych.2010.12.003_bb0060","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1471-244X-6-8","article-title":"Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia","volume":"6","author":"Ascher-Svanum","year":"2006","journal-title":"BMC Psychiatry"},{"issue":"3","key":"10.1016\/j.comppsych.2010.12.003_bb0065","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/JCP.0b013e3180582426","article-title":"All-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics. An integrated analysis","volume":"27","author":"Beasley","year":"2007","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"10.1016\/j.comppsych.2010.12.003_bb0070","doi-asserted-by":"crossref","first-page":"572","DOI":"10.4088\/JCP.08m04421","article-title":"A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia","volume":"70","author":"Kane","year":"2009","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"10.1016\/j.comppsych.2010.12.003_bb0075","doi-asserted-by":"crossref","first-page":"354","DOI":"10.4088\/JCP.v65n0311","article-title":"Adherence to conventional and atypical antipsychotics after hospital discharge","volume":"65","author":"Diaz","year":"2004","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"10.1016\/j.comppsych.2010.12.003_bb0080","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The Positive and Negative Syndrome Scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.comppsych.2010.12.003_bb0085","series-title":"Positive and negative syndrome scale (PANSS) user's manual","author":"Kay","year":"2000"},{"issue":"5","key":"10.1016\/j.comppsych.2010.12.003_bb0090","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/00004714-199710000-00010","article-title":"Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders","volume":"17","author":"Tran","year":"1997","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"10.1016\/j.comppsych.2010.12.003_bb0095","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/01.jcp.0000236658.16286.25","article-title":"Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning","volume":"26","author":"Kinon","year":"2006","journal-title":"J Clin Psychopharmacol"},{"issue":"10","key":"10.1016\/j.comppsych.2010.12.003_bb0100","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1176\/appi.ajp.162.10.1879","article-title":"Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia","volume":"162","author":"Breier","year":"2005","journal-title":"Am J Psychiatry"},{"issue":"2","key":"10.1016\/j.comppsych.2010.12.003_bb0105","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/01.jcp.0000204137.82298.06","article-title":"A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms","volume":"26","author":"Kinon","year":"2006","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.comppsych.2010.12.003_bb0110","series-title":"Diagnostic and Statistical Manual of Mental Disorders, 3rd Edition (DSM-III)","author":"American Psychiatric Association","year":"1980"},{"key":"10.1016\/j.comppsych.2010.12.003_bb0115","series-title":"Diagnostic and Statistical Manual of Mental Disorders: DSM-IV","author":"American Psychiatric Association","year":"1994"},{"key":"10.1016\/j.comppsych.2010.12.003_bb0120","series-title":"Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR","author":"American Psychiatric Association","year":"2000"},{"key":"10.1016\/j.comppsych.2010.12.003_bb0125","article-title":"Declaration of Helsinki: recommendations guiding medical doctors in biomedical research involving human subjects","author":"World Medical Association","year":"2000"},{"key":"10.1016\/j.comppsych.2010.12.003_bb0130","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1192\/bjp.151.2.145","article-title":"The symptoms of chronic schizophrenia. A re-examination of the positive-negative dichotomy","volume":"151","author":"Liddle","year":"1987","journal-title":"Br J Psychiatry"},{"issue":"4","key":"10.1016\/j.comppsych.2010.12.003_bb0135","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/BF02354306","article-title":"A new five factor model of schizophrenia","volume":"65","author":"Lindenmayer","year":"1994","journal-title":"Psychiatr Q"},{"issue":"10","key":"10.1016\/j.comppsych.2010.12.003_bb0140","doi-asserted-by":"crossref","first-page":"757","DOI":"10.4088\/JCP.v62n1003","article-title":"The effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: combined results of the North American and international trials","volume":"62","author":"Davis","year":"2001","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"10.1016\/j.comppsych.2010.12.003_bb0145","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/schbul\/10.3.388","article-title":"The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome","volume":"10","author":"Heinrichs","year":"1984","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.comppsych.2010.12.003_bb0150","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1192\/bjp.176.2.173","article-title":"Determinants of quality of life at first presentation with schizophrenia","volume":"176","author":"Browne","year":"2000","journal-title":"Br J Psychiatry"},{"issue":"12","key":"10.1016\/j.comppsych.2010.12.003_bb0155","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.4088\/JCP.v69n1208","article-title":"Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study","volume":"69","author":"Dossenbach","year":"2008","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"10.1016\/j.comppsych.2010.12.003_bb0160","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3371\/CSRP.2.3.4","article-title":"Treatment discontinuation following randomization to open-label olanzapine, risperidone or typical antipsychotics during a one-year treatment for schizophrenia","volume":"2","author":"Ascher-Svanum","year":"2008","journal-title":"Clin Schizophr Relat Psychoses"},{"issue":"3","key":"10.1016\/j.comppsych.2010.12.003_bb0165","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jpsychires.2008.06.001","article-title":"Antipsychotic treatment discontinuation in previously untreated patients with schizophrenia: 36-month results from the SOHO study","volume":"43","author":"Haro","year":"2009","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.comppsych.2010.12.003_bb0170","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1741-7015-3-21","article-title":"Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs","volume":"3","author":"Liu-Seifert","year":"2005","journal-title":"BMC Med"},{"issue":"1","key":"10.1016\/j.comppsych.2010.12.003_bb0175","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4088\/JCP.v68n0110","article-title":"Association of subjective well-being, symptoms, and side effects with compliance after 12 months of treatment in schizophrenia","volume":"68","author":"Karow","year":"2007","journal-title":"J Clin Psychiatry"},{"issue":"10","key":"10.1016\/j.comppsych.2010.12.003_bb0180","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1185\/03007995.2010.515900","article-title":"Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives","volume":"26","author":"Ascher-Svanum","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.comppsych.2010.12.003_bb0185","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1471-244X-6-45","article-title":"Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double-blind trial","volume":"6","author":"Gharabawi","year":"2006","journal-title":"BMC Psychiatry"},{"issue":"4","key":"10.1016\/j.comppsych.2010.12.003_bb0190","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/01.jcp.0000264986.32733.df","article-title":"Association of acute symptoms and compliance attitude in noncompliant patients with schizophrenia","volume":"27","author":"Liu-Seifert","year":"2007","journal-title":"J Clin Psychopharmacol"},{"issue":"10","key":"10.1016\/j.comppsych.2010.12.003_bb0195","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1097\/01.nmd.0000243082.75008.e7","article-title":"Adherence to medication and quality of life in people with schizophrenia: results of a European multicenter study","volume":"194","author":"Puschner","year":"2006","journal-title":"J Nerv Ment Dis"},{"issue":"4","key":"10.1016\/j.comppsych.2010.12.003_bb0200","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1176\/ajp.2006.163.4.611","article-title":"Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic","volume":"163","author":"Stroup","year":"2006","journal-title":"Am J Psychiatry"}],"container-title":["Comprehensive Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010440X10002051?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010440X10002051?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,4]],"date-time":"2018-12-04T17:55:53Z","timestamp":1543946153000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010440X10002051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S0010440X10002051"],"URL":"https:\/\/doi.org\/10.1016\/j.comppsych.2010.12.003","relation":{},"ISSN":["0010-440X"],"issn-type":[{"value":"0010-440X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}